Our thoracic pathology team is one of the best in the world, with expertise not only in thoracic pathology but also in thoracic cytology. We work closely with our clinical colleagues to provide multidisciplinary diagnostic expertise to MSK patients and with the Molecular Diagnostics Laboratory to assure optimal molecular diagnostic testing using the latest techniques such as next-generation sequencing.
My research in thoracic neoplasms has focused on lung cancer, malignant mesothelioma, and mediastinal thymic tumors. I have worked on classification of thoracic disorders and served as Lead Editor of the 1999 WHO Classification of Lung and Pleural Tumors as well as the 2004 and 2015 WHO Classification: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. I also led the 2011 IASLC/ATS/ERS lung adenocarcinoma classification.